The Food and Drug Administration (FDA) has approved Ryoncil ® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft vs host disease (SR-aGvHD) in pediatric patients 2 months of age ...

Multidisciplinary collaborative approach to care is required for patients with hematological malignancies in pregnancy.

Erectile dysfunction (ED) and testosterone deficiency (TD) are more common among men with testicular cancer, a new study finds. In a study of US male veterans, investigators matched 1754 patients with ...

Olverembatinib demonstrated activity in patients with CP-CML who received first- or second-generation TKIs as first-line therapy.

T-DXd outperformed physician’s choice of chemotherapy regardless of patients’ disease burden or time to progression on prior therapy.

A population-based study revealed treatment patterns among patients starting chemotherapy as first-line therapy for ...

A machine learning model can make accurate survival predictions for Merkel cell carcinoma (MCC), according to a study published online Jan. 8 in npj Digital Medicine. Noting there are no personalized ...

Precision medicine is transforming nursing roles in clinical oncology, and nurses play an increasingly crucial role in implementing personalized therapy and improving patient outcomes.

The mortality rates were 15.5% for the ibrutinib group and 16.3% for the bendamustine group. Significant cardiovascular risks are associated with ibrutinib treatment in patients with chronic ...

Mean distance in American Indian-majority census tracts reduced with adjustment for rurality but was still 3.16 times that seen in White majority tracts. HealthDay News — Differences in distance ...

Patients had a higher risk of death if they received radiotherapy in the afternoon or at night. Receiving radiotherapy in the morning may improve survival in patients with nasopharyngeal carcinoma ...

The median duration of response was 6 months. Treatment with pembrolizumab and fulvestrant provided disease control in half of patients with estrogen receptor (ER)-positive, HER2-negative ...